Mineralocorticoid receptor expression in human venous smooth muscle cells: A potential role for aldosterone signaling in vein graft arterialization

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 1, 2011, Pages

  Bafford, Richard ^a   Sui, Xin Xin ^a   Park, Min ^a   Miyahara, Takuya ^d   Newfell, Brenna G ^c   Jaffe, Iris Z ^c   Romero, Jose R ^b   Adler, Gail K ^b   Williams, Gordon H ^b   Khalil, Raouf A ^a   Conte, Michael S ^a,d  

^a University of California   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

11 hydroxysteroid dehydrogenase 2; Peripheral vascular disease; Renin angiotensin system; Vascular injury response

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SMOOTH MUSCLE FIBER; UPREGULATION; VEIN GRAFT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE; ANIMALS; ARTERIES; CAROTID ARTERIES; GENE EXPRESSION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MYOCYTES, SMOOTH MUSCLE; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; UP-REGULATION; VEINS;

EID: 79959872137     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00637.2010     Document Type: Article

References (52)

1. Guide for the Care and Use of Laboratory Animals. Institute of LaboratoryAnimal Resources, CoLS, National Research Council. Washington,DC: National Academy Press, 1996.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects oftorcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122, 2007.
3. Berceli SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, Conte MS. Surgical and endovascular revision of infrainguinalvein bypass grafts: analysis of midterm outcomes from thePREVENT III trial. J Vasc Surg 46: 1173-1179, 2007.
4. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac CardiovascSurg 116: 206-212, 1998.
5. Borland JA, Chester AH, Yacoub MH. The renin angiotensin system inbypass graft surgery. Curr Opin Cardiol 15: 371-377, 2000.
6. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia(RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153-160, 2007.
7. Brown NJ. Aldosterone and vascular inflammation. Hypertension 51:161-167, 2008.
8. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors inhuman vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008.
9. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11β-Hydroxysteroid dehydrogenase type 2 in mouse aorta: localizationand influence on response to glucocorticoids. Hypertension 42:580-587, 2003.
10. Davies MG, Fulton G, Barber L, Dalen H, Svendsen E, Hagen PO. Characterisation of angiotensin II receptor mediated responses and inhibitionof intimal hyperplasia in experimental vein grafts by the specificangiotensin II receptor inhibitor, L158,809. Eur J Vasc Endovasc Surg 12:151-161, 1996.
11. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: aunifying hypothesis. Hypertension 37: 1047-1052, 2001.
12. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellularaspects. Kidney Int 57: 1364-1369, 2000.
13. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension46: 1227-1235, 2005.
14. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO. Localizedversus systemic angiotensin II receptor inhibition of intimal hyperplasia inexperimental vein grafts by the specific angiotensin II receptor inhibitorL158,809. Surgery 123: 218-227, 1998.
15. Funder JW. Reconsidering the roles of the mineralocorticoid receptor.Hypertension 53: 286-290, 2009.
16. Funder JW. The role of aldosterone and mineralocorticoid receptors incardiovascular disease. Am J Cardiovasc Drugs 7: 151-157, 2007.
17. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone inducesangiotensin-converting-enzyme gene expression in cultured neonatal ratcardiocytes. Circulation 104: 137-139, 2001.
18. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensinII-induced hypertrophy of vascular smooth muscle cells. J Biol Chem269: 24316-24320, 1994.
19. Hausner EA, Turner MJ, Trzaskos JM, Herblin WF. Angiotensin IIreceptors in rabbit vascular grafts. Biochem Biophys Res Commun 190:27-32, 1993.
20. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate genetranscription via functional mineralocortocoid receptors in human coronaryartery smooth muscle cells. Circ Res 96: 643-650, 2005.
21. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoidreceptor activation promotes vascular cell calcification. ArteriosclerThromb Vasc Biol 27: 799-805, 2007.
22. Jiang Z, Wu L, Miller BL, Goldman DR, Fernandez CM, Abouhamze ZS, Ozaki CK, Berceli SA. A novel vein graft model: adaptation todifferential flow environments. Am J Physiol Heart Circ Physiol 286:H240-H245, 2004.
23. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensinii-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34,2000.
24. Lauth M, Cattaruzza M, Hecker M. ACE inhibitor and AT1 antagonistblockade of deformation-induced gene expression in the rabbit jugularvein through B2 receptor activation. Arterioscler Thromb Vasc Biol 21:61-66, 2001.
25. Lemarié C, Paradis P, Schiffrin E. New insights on signaling cascadesinduced by cross-talk between angiotensin II and aldosterone. J Mol Med86: 673-678, 2008.
26. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee andStroke Statistics Subcommittee. Heart disease and stroke statistics-2009update: a report from the American Heart Association Statistics Committeeand Stroke Statistics Subcommittee. Circulation 119: e21-e181, 2009.
27. Lombès M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 92:175-182, 1995.
28. Lombès M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascularmineralocorticoid receptor. Circ Res 71: 503-510, 1992.
29. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosteronepotentiates angiotensin II-induced signaling in vascular smooth musclecells. Circulation 109: 2792-2800, 2004.
30. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiologicaland pathological effects in the cardiovascular system. Am J Physiol CellPhysiol 292: C82-C97, 2007.
31. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosteroneand angiotensin II synergistically induce mitogenic response in vascularsmooth muscle cells. Circ Res 97: 434-442, 2005.
32. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunologicalmechanisms in the pathophysiology of vein graft intimalhyperplasia. Immunol Cell Biol 84: 115-124, 2006.
33. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesterylester transfer protein inhibition, high-density lipoprotein raising, andprogression of coronary atherosclerosis: insights from ILLUSTRATE(Investigation of Lipid Level Management Using Coronary Ultrasound toAssess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514, 2008.
34. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapibon the progression of coronary atherosclerosis. N Engl J Med 356:1304-1316, 2007.
35. Nowygrod R, Egorova N, Greco G, Anderson P, Gelijns A, Moskowitz A, McKinsey J, Morrissey N, Kent KC. Trends, complications, andmortality in peripheral vascular surgery. J Vasc Surg 43: 205-216, 2006.
36. O'Donohoe MK, Davies MG, Radic ZS, Mikat EM, Hagen PO. Increased concentrations of angiotensin-converting enzyme in the intimalhyperplasia of experimental vein grafts. J Cardiovasc Pharmacol 23:594-601, 1994.
37. O'Donohoe MK, Schwartz LB, Radic ZS, Mikat EM, McCann RL, Hagen PO. Chronic ACE inhibition reduces intimal hyperplasia in experimentalvein grafts. Ann Surg 214: 727-732, 1991.
38. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalenceof peripheral arterial disease and risk factors in persons aged 60 and older:data from the national health and nutrition examination survey 1999-2004. J Am Geriatr Soc 55: 583-589, 2007.
39. Owens CD, Ho KJ, Conte MS. Lower extremity vein graft failure: atranslational approach. Vasc Med 13: 63-74, 2008.
40. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-AcuteMyocardial Infarction Heart Failure Efficacy and Survival StudyInvestigators. Eplerenone, a selective aldosterone blocker, in patientswith left ventricular dysfunction after myocardial infarction. N Engl J Med348: 1309-1321, 2003.
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity andmortality in patients with severe heart failure. Randomized AldactoneEvaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
42. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascularinflammatory phenotype in the rat heart. Am J Physiol Heart CircPhysiol 283: H1802-H1810, 2002.
43. Rowe VL, William L, Fred AW, David E. Patterns of treatment forperipheral arterial disease in the United States: 1996-2005. J Vasc Surg49: 910-917, 2009.
44. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone onvascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 63:1522-1527, 1985.
45. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion byattenuation of oxidative stress and inflammation. Arterioscler ThrombVasc Biol 26: 917-921, 2006.
46. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating thephysiological and pathophysiological actions of angiotensin II in vascularsmooth muscle cells. Pharmacol Rev 52: 639-672, 2000.
47. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, Dupuis B, Lablanche JM, Bertrand ME. Neointimalthickening after balloon denudation is enhanced by aldosterone andinhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res29: 27-32, 1995.
48. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y. Eplerenone suppresses neointimal formation after coronary stent implantationin swine. Int J Cardiol 107: 260-266, 2006.
49. Wang GJ, Sui XX, Simosa HF, Jain MK, Altieri DC, Conte MS. Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosisprotein. Arterioscler Thromb Vasc Biol 10: 2081-2087, 2005.
50. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A. Eplerenonesuppresses constrictive remodeling and collagen accumulation after angioplastyin porcine coronary arteries. Circulation 104: 467-472, 2001.
51. Xiao F, Puddefoot JR, Vinson G. Aldosterone mediates angiotensinII-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol165: 533-536, 2000.
52. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosteronepotentiation of angiotensin II-stimulated rat arterial smooth musclecell proliferation. Hypertension 44: 340-345, 2004.